Skip to main content

Weight-Loss Drug Zepbound May Work Better in Women Than Men

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 12, 2024.

By Dennis Thompson HealthDay Reporter

THURSDAY, Sept. 12, 2024 -- The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis of the clinical trials that led to its approval.

All doses of tirzepatide consistently reduced weight in both women and men, researchers found.

But women lost up to 25% of their initial body weight when treated with tirzepatide, compared with just 19% in men, results showed.

Researchers presented the new analysis Wednesday at the European Association for the Study of Diabetes’ annual meeting in Madrid. Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.

“This post-hoc analysis underscores the consistent benefits of tirzepatide for women and men. More research is needed to understand the mechanism by which females may experience more weight reduction in these trials,” lead researcher Dr. Luis-Emilio García, an associate vice president at Eli Lilly, said in a meeting news release.

Tirzepatide works by mimicking two types of hormones related to hunger and insulin control, GLP-1 and GIP. Its rival drug, Wegovy, only mimics GLP-1.

This new study pooled all the data from four trials that tested tirzepatide against a placebo in nearly 3,000 women and 1,700 men.

The trials tested the weight-loss drug in obese people with or without type 2 diabetes or other weight-related health problems. Some trials also included a three-month lifestyle intervention intended to help people shed pounds.

Across all trials, people’s odds of reaching weight-reduction targets were significantly higher when they took tirzepatide than when they received a placebo.

Women lost 12% to 28% more weight on tirzepatide than placebo, while men lost 9% to 19% compared to placebo.

The safety profile was similar for men and women, although more women reported nausea and vomiting.

The trials were all funded by Eli Lilly, the maker of Zepbound.

Sources

  • European Association for the Study of Diabetes, news release, Sept. 11, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted September 2024

Read this next

Shedding Pounds in Middle Age Could Add Years to Your Life, Study Finds

WEDNESDAY, May 28, 2025 — Losing just 6.5% of body weight in midlife may lower later risk of disease and premature death, new research shows. Researchers found that people...

Preschool BMI Can Predict Childhood Obesity Risk

WEDNESDAY, May 28, 2025 — Preschoolers who don’t naturally lose weight are more likely to develop full-fledged childhood obesity by age 9, a new study says. Most kids...

Weight-Loss Drugs May Lower Risk Of Obesity-Related Cancers

WEDNESDAY, May 28, 2025 — Popular GLP-1 weight loss drugs like Ozempic and Zepbound can help reduce a woman’s risk for as many as 14 cancers associated with obesity, a...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.